Molecular Imaging Agents

Our products and solutions help healthcare providers and therapy innovators to make more informed and earlier diagnosis, monitor disease more accurately and develop tailored patient treatment plans across major care pathways.


innovative solutions launched in 15 years


patients served every year

3 cGMP

certified molecular imaging production facilities globally


doses delivered worldwide for clinical trials since 2018


Through molecular imaging product websites, Middle East based healthcare professionals will be able to access key product information, materials and prescribing information.
Our focus is on precision medicine – an innovative approach to tailoring disease prevention and diagnosis with the best possible treatment pathway. We bring clinically relevant applications to our healthcare professionals and work to improve access to nuclear medicine – transforming patient outcomes.

Accelerating therapeutic research to improve patient lives

Our Pharma Services offering provides access to GE Healthcare's tracer portfolio, which can be tailored to the needs of your clinical study. Our biomarkers enable you to select the right patients, and monitor patient progression long-term, so you can test your hypothesis more accurately.

We also have an established global network of suppliers, and a dedicated in-house team, supporting you in keeping your project on track. Our many years of experience in managed dose supply mean that you can plan and schedule patients with confidence.

Molecular imaging can support the research and development of treatments that can take advantage of the body’s own immune system to help fight cancer.

Our growing understanding of patients' immune responses is aiding the development of PET diagnostic tools for clinical management of immunotherapy patients, to help in identifying patients who are more likely to respond, avoiding unnecessary treatment and reducing adverse events. We develop these tools by collaborating with third parties and leading academic institutions like Vanderbilt University Medical Center in the USA.

We are committed to bringing innovative solutions to patients.

We welcome the opportunity to collaborate with leading academic institutions, biotech and pharmaceutical companies to innovate in molecular imaging across disease areas to enable clinicians to better diagnose, treat and monitor complex diseases and to advance care for patients with unmet needs. For information on business development or partnering opportunities, please contact us below registering your interest about our Pharmaceutical Diagnostics Licensing department.

We use software to analyse complex medical data and relationships between prevention, or treatment techniques, and patient outcomes.

Our quantification software enables visual evaluation and quantification of SPECT and PET images, allowing clinicians to remotely access and review clinical images from virtually any computer system anytime, anywhere in the world.

Also our Edison™ Platform offers integrated artificial intelligence powered technologies, helping you make sound diagnostic decisions, operate at peak efficiency and deliver positive patient outcomes.
JB00422AFG 05-2023